Amyloid plaque imaging in vivo: current achievement and future prospects
Amyloid plaque imaging in vivo: current achievement and future prospects
复制标题
DOI：
10.1007/s00259-007-0700-2
复制
发表时间：
2008-03-01
影响因子：
9.1
通讯作者：
Nordberg, Agneta
中科院分区：
文献类型：
--
作者：
Nordberg, Agneta
阿尔茨海默病（Alzheimer's disease，AD）是一种非常复杂的神经退行性疾病，其确切病因至今仍不清楚。Alois Alzheimer已经描述了主要的组织病理学特征，即淀粉样蛋白斑块和神经原纤维缠结，几十年来一直是研究的焦点。尽管可能的整个级联事件在大脑中导致认知障碍，淀粉样蛋白仍然是诊断和treatment.Discussion分子成像技术的快速发展，现在允许成像的淀粉样蛋白斑块在体内阿尔茨海默病患者的PET淀粉样蛋白配体，如匹兹堡化合物B（PI B）。到目前为止的研究已经揭示了在AD的前驱期大脑中的高C-11-PIB保留，以及通过C-11-PIB将AD与其他痴呆疾病区分开的可能性。正在进行的研究是集中在了解脑和CSF淀粉样蛋白过程和认知processes.Conclusion在体内成像的淀粉样蛋白将是重要的早期诊断和评估新的抗淀粉样蛋白治疗AD之间的关系。
Introduction Alzheimer's disease (AD) is a very complex neurodegenerative disorder, the exact cause of which is still not known. The major histopathological features, amyloid plaques and neurofibrillary tangles, already described by Alois Alzheimer, have been the focus in research for decades. Despite a probable whole cascade of events in the brain leading to impairment of cognition, amyloid is still the target for diagnosis and treatment.Discussion The rapid development of molecular imaging techniques now allows imaging of amyloid plaques in vivo in Alzheimer patients by PET amyloid ligands such as Pittsburgh compound B (PIB). Studies so far have revealed high C-11-PIB retention in brain at prodromal stages of AD and a possibility to discriminate AD from other dementia disorders by C-11-PIB. Ongoing studies are focussing to understand the relationship between brain and CSF amyloid processes and cognitive processes.Conclusion In vivo imaging of amyloid will be important for early diagnosis and evaluation of new anti-amyloid therapies in AD.